Search details
1.
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 395(10240): 1835-1844, 2020 06 13.
Article
in English
| MEDLINE | ID: mdl-32534646
2.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Lancet Oncol
; 17(6): 791-800, 2016 Jun.
Article
in English
| MEDLINE | ID: mdl-27179402
3.
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study.
Breast Cancer Res
; 16(4): R73, 2014 Jul 08.
Article
in English
| MEDLINE | ID: mdl-25005255
4.
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
Anticancer Drugs
; 24(10): 1084-92, 2013 Nov.
Article
in English
| MEDLINE | ID: mdl-23969513
5.
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
J Immunother Cancer
; 11(10)2023 10.
Article
in English
| MEDLINE | ID: mdl-37903590
6.
The Effects of a Low Sodium Meal Plan on Blood Pressure in Older Adults: The SOTRUE Randomized Feasibility Trial.
Nutrients
; 13(3)2021 Mar 16.
Article
in English
| MEDLINE | ID: mdl-33809796
7.
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.
Oncoimmunology
; 9(1): 1824645, 2020 10 05.
Article
in English
| MEDLINE | ID: mdl-33101774
8.
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.
J Natl Cancer Inst
; 111(1): 69-77, 2019 01 01.
Article
in English
| MEDLINE | ID: mdl-29788230
9.
Design, synthesis and enzymatic evaluation of 6-bridged imidazolyluracil derivatives as inhibitors of human thymidine phosphorylase.
J Pharm Pharmacol
; 59(4): 537-47, 2007 Apr.
Article
in English
| MEDLINE | ID: mdl-17430637
10.
Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
Cancer Chemother Pharmacol
; 79(2): 353-361, 2017 02.
Article
in English
| MEDLINE | ID: mdl-28074265
11.
Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.
Curr Pharm Des
; 8(15): 1319-33, 2002.
Article
in English
| MEDLINE | ID: mdl-12052210
12.
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Cancer Chemother Pharmacol
; 74(4): 819-29, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-25119184
13.
A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
Clin Lung Cancer
; 13(6): 432-41, 2012 Nov.
Article
in English
| MEDLINE | ID: mdl-22609229
14.
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
J Clin Oncol
; 28(7): 1138-44, 2010 Mar 01.
Article
in English
| MEDLINE | ID: mdl-20124182
15.
Synthesis and enzymatic evaluation of pyridinium-substituted uracil derivatives as novel inhibitors of thymidine phosphorylase.
Bioorg Med Chem
; 10(3): 525-30, 2002 Mar.
Article
in English
| MEDLINE | ID: mdl-11814838
Results
1 -
15
de 15
1
Next >
>>